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scores were compared to corresponding 10 year ACM predictions from the CDM. 
Base case (BC) analyses applied UKPDS-68 risk equations (UK68-RE) for CV risk and 
mortality. Two sets of sensitivity analyses were conducted using UK68-RE for CV risk 
but mortality tracked individually per complication event (non combined mortality 
approach) (SA1) and UKPDS-82 risk equations (UK82-RE) applied for CV risk and 
mortality (SA2). Results: Across all age and co-morbidity states, CDM simulations 
demonstrated the closest match to CCI-scores in SA1 with an R2-statistic of 0.877. 
This compared to R2-statistics of 0.757, and 0.851 for BC and SA2, respectively. BC 
and SA2 analyses noteworthy underestimated ACM risk in analyses with increased 
co-morbitity level by 68% (BC) and 49% (SA2) vs. 17% (SA1) in (MI+S+HF) and 44% 
(BC) and 36% (SA2) vs. 3% (SA1) in (MI+S+HF+RF). ConClusions: The CDM dem-
onstrated a closer match to CCI mortality scores (vs. outcome studies) with a trend 
to underestimate ACM. This trend increased with baseline age and (only BC and 
SA2) co-morbidity level.
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objeCtives: Multivariate functions can be used to predict individual risk for car-
diovascular (CVD) events and also to estimate baseline risk in economic models. 
We present a comparison of deterministic versus stochastic risk predictions using 
Framingham’s [D’Agostino 2008] and REACH’s [Wilson 2012] functions. Stochastic 
risk prediction accounts for patient-level heterogeneity, but involves a number of 
issues including increased complexity, data requirements, need for assumptions 
and computational burden. To our knowledge, this topic has not been studied in the 
CVD setting. Methods: D’Agostino 2008 and Wilson 2012 modeled primary (PE) and 
recurrent event (RE) risks, respectively. Both studies considered fatal and non-fatal 
aggregate CVD events and estimated a Cox Proportional Hazards (CPH) multivariate 
risk function. In the deterministic prediction, the means of the risk factors were 
used to predict the population’s risk directly from the functions. In the stochastic 
prediction, individual patient profiles (n= 10,000) were generated using Monte Carlo 
simulation. Individual risks were then estimated from the functions and averaged 
to compute the population’s risk. Multinomomial distributions were assumed for 
discrete variables (e.g. diabetes, number of vascular beds) and normal or log-normal 
distributions were assumed for continuous variables depending on skewness (e.g. 
age, total cholesterol). Probability distributions were parameterized based on the risk 
factors descriptives reported in the original references. Simulations were performed 
with and without considering dependence of risk factors. Results: Due to the non-
linearity of the CPH function, the stochastic prediction yielded 23% (PE) and 17% 
(RE) higher risks than the deterministic approach (14% and 10%, respectively, if age 
was kept constant). Differences between prediction approaches are even higher if 
the estimated correlation structure of risk factors is accounted for. ConClusions: 
When compared to the stochastic prediction, the deterministic approach leads to 
lower estimates of CVD risks. Therefore, economic models using this approach 
might underestimate treatment effect.
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objeCtives: To present an alternative implementation for the conventional Markov 
models with area under the curve (AUC) approach: the continuous model (CM). 
To present how the CM avoids the need of determining cycles in theory and to 
compare the traditional and the CM approach in terms of results and complex-
ity in an oncology model example. Methods: The AUC model assumes that the 
survival function is known at any timepoint not only at the beginning and end of 
model cycle. The CM calculates the model outcomes for the whole timehorizon by 
using the values of the survival function in every timepoint, instead of the discrete 
timepoints defined by cycle length. The CM approach overcomes the issue of the 
artificial characterization of time using cycles, that is often criticized in Markov 
models. Using CM can also lead to more precise estimates. A simple oncology AUC 
model with three health states (progression free survival, progression and death) 
and four-weekly cycles was built and converted to a CM model in Excel®, using 
user defined Visual Basic functions. Results, generalizability and user friendliness 
were compared. Results: The results of the two models were similar: for health 
outcomes differences were around 1%, for costs and incremental cost-effectiveness 
ratios around 0.5%. Calculations were done in a single cell/outcome instead of a 
column of 100-200 cells depending on cycle length and time horizon, giving less 
scope for bugs and facilitating easier debugging. As a result the implementation of 
the CM model was faster and technical validation easier. ConClusions: The CM 
approach requires more technical background from the developer; custom func-
tions have to be built even for point estimates. However, results of a CM, requires 
smaller spreadsheet space, and provides more transparency and easier debugging, 
while providing similar or potentially more precise estimates compared to the AUC 
model results.
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objeCtives: Markov models are a currently popular means of estimating the cost-
effectiveness of interventions; however they are associated with certain limitations 
which may make them ill-suited to inform some health care decisions. Patient simu-
lation models offer an alternative methodology which may overcome some of these 
and € 47,000/QALY for the remaining two models. Differences in the outcomes could 
mainly be explained by differences in input values for disease progression, exacer-
bation-related mortality and all-cause mortality with high input values resulting 
in low ICERs and vice versa. Lifetime results were mainly influenced by the input 
values for mortality. The probability of intervention four to be cost-effective at a 
willingness-to-pay of € 50,000/QALY was 90-100% for five models and about 70% and 
50% for the other two models. ConClusions: Mortality was the most important 
factor determining the differences in cost-effectiveness outcomes between models.
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objeCtives: The risk of cardiovascular (CV) events in post myocardial infarction 
(MI) patients poses a significant burden on the UK health care system despite the 
current standard of care (SoC). The objective of this analysis was to develop a model 
to quantify the relationship between efficacy and outcomes of a new hypothetical 
drug given in addition to current SoC to reduce the risk of CV events in post-MI 
patients when compared to SoC. Methods: A 6-state lifetime Markov model with 
a 1-year cycle length was developed from a UK health care perspective. Recurrent 
MI, stroke and CV death were modeled. The hypothetical drug was assigned efficacy 
values for its ability to reduce the incidence of CV events. The outcomes were meas-
ured in terms of QALYs and LYs. A linear regression model was fitted to estimate 
the expected outcome/patient based on relative risk reduction (RRR) in the inci-
dence of CV events. All outcomes were discounted at 3.5% annually. Results: The 
model structure addressed some of the limitations of previous economic models, 
namely increased risk due to stroke in MI patients and increased risk of subse-
quent events in the first year. For identical cohorts, the outcomes from the model 
compared well with other published studies. For a cohort of patients aged 40-years, 
the model predicted on an average, LYs of 17.6 and QALYs of 13.64. A hypothetical 
drug achieving a 5% RRR in CV events resulted in an incremental LYs of 0.28 and 
QALYs of 0.23. The increase in incremental QALYs and LYs per percentage point 
reduction in relative risk as compared to SoC was estimated to be 0.043 and 0.054 
respectively. ConClusions: A de-novo economic model quantifies the relationship 
between the efficacy and outcomes of a hypothetical drug when compared to the 
SoC to reduce the risk of CV events in post-MI patients.
PRM86
estiMating the lifetiMe health outcoMes of tyPe 2 Diabetes 
Mellitus (t2DM) Patients inaDequately contRolleD on MetfoRMin 
Plus sulPhonyluRea ReceiVing eitheR canagliflozin oR sitagliPtin 
using the ukPDs outcoMes MoDel V1.3
Nuhoho S.1, Worbes-Cerezo M2
1Janssen-Cilag A/S, Birkerød, Denmark, 2Janssen-Cilag UK, High Wycombe, UK
objeCtives: The goals of type 2 diabetes management are to control glycaemia and 
other micro- and macrovascular risk factors such as weight, blood pressure and lipids 
in order to prevent death and other complications due to the disease. The natural 
history of the disease makes it challenging to estimate the effects of treatments on 
these long term complications and mortality from standard clinical trials. Modelling 
is therefore a key bridging tool for predicting long term health outcomes from inter-
mediate endpoints. The objective of this analysis was to estimate the relative effects 
of canagliflozin 300mg and sitagliptin 100mg on mortality, micro- and macrovascular 
complications in T2DM patients in triple line as add on to metformin plus sulpho-
nylurea using the UKPDS Outcomes Model v1.3. Methods: A probabilistic patient 
generator was developed which generated 10,000 patients with applied treatment 
effects based on data from head to head randomised clinical trials. Upon loss of 
glycaemic control (HbA1c ≥ 7%), patients were assumed to switch to insulin. 1% point 
reduction in HbA1c was applied on rescue. For model stability, patients were looped 
1,000 times (creating 10 million patients in each arm) with 100 bootstrap simulations. 
Outcomes were discounted 3.5% annually. Results: At the end of the 40 years simu-
lation, patients initiating canagliflozin 300mg had 49 more survivors and 16,918 fewer 
diabetes-related deaths. Micro- and macrovascular complications were estimated 
in fewer patients on canagliflozin 300mg than on sitagliptin 100mg (between 5,948 
fewer renal failures and 41,157 fewer myocardial infarctions). There were discernible 
relative risk reductions in all complications and diabetes-related death ranging from 
1.40% (heart failure) to 2.96% (amputation). ConClusions: Results of the analysis 
using the UKPDS Outcomes Model v1.3 suggest that canagliflozin 300mg compared 
with sitagliptin 100mg as add on to metformin plus sulphonylurea reduces long-term 
diabetes-related mortality and complications.
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objeCtives: All cause mortality (ACM) validations with the IMS CORE Diabetes 
Model (CDM) have demonstrated below average fit when compared to overall vali-
dation scores from 96 validation end points (EP) with a R2-statistic of 0.651 (vs. 
0.93 All-EP). Lack of fit was associated with a model overestimation of ACM when 
compared to contemporary outcome studies (ACCORD, ADVANCE, VADT). The objec-
tive of this investigation was to put these findings into perspective by compar-
ing the model to mortality risk predictions from the Charlson-Comorbidity-Index 
(CCI). Methods: The CCI was applied to predict the 10 year mortality risk for diabe-
tes patients with age of 50,60,70 and 80 years and four different co-morbidity levels: 
no complications (NC), myocardial infarction (MI), MI and stroke (MI+S), MI+S and 
heart failure (MI+S+HF) and MI+S+HF and renal failure (MI+S+HF+RF). CCI mortality 
